Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
RESEARCH TOOLSreports
Holding SLN?
Track your performance easily
SLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.51 - $27.72
Previous Close$18.08
Volume64.83K
Average Volume (3M)200.52K
Market Cap
$843.61M
Enterprise Value$850.27M
Total Cash (Recent Filing)£54.03M
Total Debt (Recent Filing)£59.18M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 12, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding46,800,000
10 Day Avg. Volume144,129
30 Day Avg. Volume200,524
Standard Deviation0.23
R-Squared0.07
Alpha0.00801
Financial Highlights & Ratios
Price to Book (P/B)7.53
Price to Sales (P/S)35.29
Price to Cash Flow (P/CF)-25.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$57.20Price Target Upside216.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics Reports Increased Losses
Ownership Overview
―
Insiders
0.13% Mutual Funds
0.08% Other Institutional Investors
99.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $6.51 and its highest was $27.72 in the past 12 months.
What is Silence Therapeutics’s market cap?
Currently, no data Available
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Aug 15, 2024. The company reported -$0.143 earnings per share for the quarter, missing the consensus estimate of -$0.115 by -$0.028.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -$0.13.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,659,940 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.143 in its last earnings report, missing expectations of -$0.115. Following the earnings report the stock price went up 3.137%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Among the largest hedge funds holding Silence Therapeutics’s share is Duquesne Family Office LLC. It holds Silence Therapeutics’s shares valued at 7M.
---
Silence Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.20 (216.37% Upside)
$57.20 (216.37% Upside)
Blogger Sentiment
Bullish
SLN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 147.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
149.03%
12-Months-Change
Fundamentals
Return on Equity
-63.79%
Trailing 12-Months
Asset Growth
102.31%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
SLN Company Deck
---
SLN Earnings Call
Q4 2024
0:00 / 0:00
---
SLN Stock 12 Month Forecast
Average Price Target
$57.20
▲(216.37% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering SLN
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+94.30%
reiterated a buy rating 20 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +94.30% per trade.
---